-
Syntrix to present at 2025 Life Science Innovation Northwest (LSINW)
-AUBURN, WASHINGTON — Syntrix Pharmaceuticals is pleased to announce that it has been invited to present development and financing goals…
0 -
ASCO 2024 selects SX-682 for oral podium presentation of positive first-in-class efficacy results in patients with metastatic melanoma
-– Safety and efficacy data will be presented for first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab in patients with…
-
New study finds SX-682 leads to “unprecedented” response and cures in pancreatic cancer models
-AUBURN, WASHINGTON —A new study led by researchers at MD Anderson Cancer Center revealed for the first time that SX-682…
-
First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
-— Phase 1 Findings Presented in Oral Session at 2022 American Society of Hematology (ASH) Meeting Support CXCR1/2 as Promising…
-
New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer
-A new study led by researchers at NYU Grossman School of Medicine and its Laura and Isaac Perlmutter Cancer Center…
-
Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies
-Researchers at the Fred Hutchinson Cancer Research Center and the National Institutes of Health (NIH) independently showed SX-682 eradicates pivotal…
-
Syntrix Pharmaceuticals to Present Positive Desmetramadol Trial Results at the 2019 Pain Management SUMMIT
-Desmetramadol trial featured on the October cover of The Journal of Pain AUBURN, WASHINGTON — Syntrix Pharmaceuticals, Inc., a leading…
-
Syntrix Announces Dosing of First Patient in Phase 1/2 Clinical Trial of SX-682 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Melanoma
-– Initial Clinical Data Expected in First Half of 2020 – AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced that it…
-
Syntrix Reports Positive Clinical Trials Showing Desmetramadol Has the Analgesic and Side Effect Profile of Tramadol Without Its Metabolic Liabilities
-Study successfully met its endpoints and provides basis for pivotal Phase 3 trial AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced…
-
Researchers Report SX-682 Could Enhance Multiple Forms of T Cell-Based Immunotherapies in Solid Tumors
-Researchers at the National Institutes of Health (NIH) have shown that inhibition of myeloid-derived suppressor cell (MDSC) trafficking into mouse…
News
Syntrix Pharmaceuticals > News